sodium-pertechnetate-tc-99m has been researched along with Prostatic-Neoplasms* in 6 studies
1 review(s) available for sodium-pertechnetate-tc-99m and Prostatic-Neoplasms
1 trial(s) available for sodium-pertechnetate-tc-99m and Prostatic-Neoplasms
Article | Year |
---|---|
Different biodistribution of 99mTc-labelled chimeric mouse-human monoclonal antibody between athymic mice model and human.
Biodistribution of chimeric mouse/human monoclonal antibody against non-specific cross-reacting antigen (chNCA Ab) was studied in athymic mice and patients with metastatic bone disease. 99mTc-chNCA Ab showed a high labelling efficiency, stability and also a high binding ratio to human granulocytes. Since NCA showed cross-reactivity with carcinoembryonic antigen (CEA), animal experiments showed that 99mTc-chNCA Ab was accumulated in the xenografted tumour which expressed CEA, suggesting the preserved immunoreactivity of labelled materials. In the clinical study, injected 99mTc-chNCA Ab formed a high molecular weight complex immediately after intravenous administration and was trapped mainly in liver. The first-phase plasma half-life was 6.4 +/- 1.1 min. None of the patients showed adverse reaction or human antimurine or anti-chimeric antibody in their serum. 99mTc-chNCA Ab demonstrated remarkably different biodistribution between patients and the animal model and showed different pharmacokinetics from other murine and chimeric Abs reported previously. For safety HPLC analysis should be performed before clinical radioimmunodetection or radioimmunotherapy by incubating radiolabelled MAb with human serum under strict conditions. Topics: Aged; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Cell Adhesion Molecules; Colorectal Neoplasms; Humans; Immunoconjugates; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Transplantation; Prostatic Neoplasms; Radioimmunodetection; Recombinant Fusion Proteins; Sodium Pertechnetate Tc 99m; Tissue Distribution | 1996 |
4 other study(ies) available for sodium-pertechnetate-tc-99m and Prostatic-Neoplasms
Article | Year |
---|---|
Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials.
This study was done to aid in the design of a phase I gene therapy trial in patients with prostate cancer. We determined the dosimetric characteristics of our reporter gene system when coupled with intravenous administration of radioactive sodium pertechnetate (Na(99m) TcO(4)) and determined the feasibility of using human sodium iodide symporter (hNIS) as a reporter gene to study the dynamics of adenoviral transgene expression in a large animal tumor. A replication-competent Ad5-yCD/mutTK(SR39) rep-hNIS adenovirus was injected into the prostate gland of dogs for dosimetry purposes, and into a canine soft tissue sarcoma (STS) for imaging purposes. After resection of the prostate, the amount of (99m)TcO(4)() sequestered in the prostate was determined, the radiation dose absorbed by the prostate and nontarget critical organs was calculated, and hNIS reporter gene expression was imaged in the STS by single-photon emission computed tomography (SPECT). On the basis of the findings from 25 dogs, the amount of (99m)TcO (4)() sequestered in the prostate ranged from 13 to 276 muCi. Using the highest value observed, absorbed radiation dose to critical organs was calculated and found to be below U.S. Food and Drug Administration limits for diagnostic imaging. Also, (99m)TcO (4)() uptake was readily detected by SPECT and found to persist in vivo for at least 4 days. On the basis of our dosimetry calculations, up to five imaging procedures can be safely performed in humans after intraprostatic injection of the Ad5-yCD/mutTK(SR39)rep-hNIS adenovirus and the hNIS reporter gene system can be used to study the dynamics of adenoviral gene therapy vectors in large animal tumors. Topics: Animals; Clinical Trials, Phase I as Topic; Dogs; Genes, Reporter; Genetic Therapy; Genetic Vectors; Humans; Male; Prostatic Neoplasms; Radiographic Image Interpretation, Computer-Assisted; Research Design; Sodium Pertechnetate Tc 99m; Symporters; Tissue Distribution | 2007 |
Dual-isotope protocol for indium-111 capromab pendetide monoclonal antibody imaging.
A dual-isotope imaging protocol using 99mTc-labeled red blood cells with 111In capromab pendetide monoclonal antibody imaging for detective and localizing nodal metastasis in prostate cancer is described.. This protocol involves a single SPECT acquisition that is less time consuming and more comfortable for the patient than the currently recommended method, which requires two separate SPECT acquisitions performed on different days.. Forty patients were studied with the dual-isotope protocol. Preliminary data suggest increased accuracy compared with the single-isotope technique.. The dual-isotope technique assures the precise image registration needed for accurate comparison of blood pool and pelvic lymph node activity that is required for confident and accurate image interpretation. Topics: Antibodies, Monoclonal; Data Display; Erythrocytes; Humans; Image Processing, Computer-Assisted; Indium Radioisotopes; Lymph Nodes; Lymphatic Metastasis; Male; Prostatic Neoplasms; Radioimmunodetection; Radiopharmaceuticals; Reproducibility of Results; Sodium Pertechnetate Tc 99m; Time Factors; Tomography, Emission-Computed, Single-Photon | 1998 |
Improved intrinsic resolution: does it make a difference? Concise communication.
The purpose of this study was to determine what effect further improvement in an Anger camera's intrinsic resolution has on lesion detection. We studied 52 patients undergoing bone imaging and 58 undergoing liver imaging. All patients had images performed in rapid sequence on ZLC -75 and ZLC -37 Anger cameras, both by Siemens. The two imaging systems are virtually identical except for the number of photomultiplier tubes and crystal thickness; these resulted in differences in intrinsic resolution ( ZLC -75 less than 3.8 mm FWHM at 140 keV, ZLC -37 less than 4.9 mm) and sensitivity ( ZLC -75 approximately 0.91 of ZLC -37 at 140 keV). Observer performance, measured by ROC curves, for detection of abnormalities was virtually identical with the two instruments. Subjectively, there was a trend toward preference of the ZLC -75 images, but this was not associated with any significant improvement in lesion detectability even in the subgroup in which a preference for one or the other instrument was noted. Topics: Bone and Bones; Breast Neoplasms; Female; Humans; Image Enhancement; Liver; Lung Neoplasms; Male; Prostatic Neoplasms; Radionuclide Imaging; Sodium Pertechnetate Tc 99m; Sulfur; Technetium; Technetium Tc 99m Sulfur Colloid | 1984 |
Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase.
Conventional antibodies against prostatic acid phosphatase, labeled with iodine-131, have been administered to patients with prostatic carcinoma for the external scintigraphic imaging of tumors containing prostatic acid phosphatase (radioimmunodetection). The method has been found to be safe and reliable for imaging of primary tumors and non-bone metastases, even differentiating between lung tumors of prostatic and pulmonary origin. Topics: Acid Phosphatase; Animals; Antibodies; Bone Neoplasms; Carcinoma; Goats; Humans; Iodine Radioisotopes; Isotope Labeling; Lung Neoplasms; Male; Prostate; Prostatic Neoplasms; Rabbits; Radionuclide Imaging; Serum Albumin; Sodium Pertechnetate Tc 99m; Technetium; Technetium Tc 99m Aggregated Albumin | 1984 |